Why the study?
Does AZD6140 improve ADP-induced platelet inhibition and reduce response variability compared to clopidogrel in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes and those undergoing percutaneous interventions
Comparison
AZD6140 vs Clopidogrel (thienopyridine therapy)
Design
Review
Authors
Loading...
May support ACS patients needing rapid offset; leaves open whether superior inhibition improves outcomes.
Does AZD6140 improve ADP-induced platelet inhibition and reduce response variability compared to clopidogrel in patients with acute coronary syndromes?
AZD6140 is a novel, reversible P2Y12 inhibitor that offers superior platelet inhibition and faster onset/offset compared to clopidogrel, potentially benefiting patients who may require immediate surgery.
Tantry et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: